Evidence map›Paper›PMID 41264095›Full record

ArticleActa neuropathologica2025

Genetic variation in TMEM106B alters microglial activation and cytokine responses in chronic traumatic encephalopathy.

Shahar Hartman, Nurgul Aytan, Raymond Nicks, Samantha Hawkins, Jonathan Cherry, Victor E Alvarez, Gaoyuan Meng, Yorghos Tripodis, Brett Martin, Joseph Palmisano and 10 more

Abstract read
In one paragraph

Article in Acta neuropathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Shahar HartmanBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Nurgul AytanBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Raymond NicksBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Samantha HawkinsBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Jonathan CherryBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Victor E AlvarezBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Gaoyuan MengVA Bedford Healthcare System, Bedford, MA, USA.
Yorghos TripodisBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Brett MartinBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Joseph PalmisanoBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Lee E GoldsteinBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Douglas I KatzDepartment of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Brigid DwyerDepartment of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Daniel H DaneshvarDepartment of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA.
John F CraryDepartment of Pathology, Nash Family Department of Neuroscience, Department of Artificial Intelligence & Human Health, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Michael AloscoBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Weiming XiaVA Bedford Healthcare System, Bedford, MA, USA.
Ann C McKeeBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Jesse MezBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA.
Thor D SteinBoston University Alzheimer's Disease Research Center and CTE Center, Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, USA. tdstein@bu.edu.

Funding

Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Margaret Sewell · 2020 to 2026
$31.0M
FRAMINGHAM HEART STUDY - YEAR 5 EXAM75N92019D00031 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · 2019 to 2024
$29.8M
Neuropathology CoreP30AG013846 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOWALL, NEIL W. · 1996 to 2020
$29.1M
RL5: Research Education CoreP30AG072978 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Ann C. McKee · 2021 to 2026
$25.6M
Recurrent Hemorrhagic Stroke in Minority PopulationsR01NS093870 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI JONATHAN ROSAND, Amytis Towfighi · 2016 to 2026
$12.3M
Traumatic Brain Injury and Repetitive Head Impacts: Contributions to AD/ADRD and CTE Neuropathology and Resulting Clinical SyndromesU54NS115266 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MCKEE, ANN C. · 2019 to 2023
$10.3M
Risk and Resilience, Clinical presentation, and Biomarker Profiles of Chronic Traumatic Encephalopathy and Related Dementias: The DIAGNOSE CTE Research Project IIR01NS139383 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Michael Alosco, Nicholas Ashton · 2024 to 2026
$9.3M
CTE and Posttraumatic Neurodegeneration: Neuropathology and Ex Vivo ImagingU01NS086659 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MCKEE, ANN C. · 2014 to 2017
$6.1M
Leveraging Existing Aging Research Networks to investigate TBI and AD/ADRD risk (LEARN TBI & AD)R01AG061028 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DAMS-O'CONNOR, KRISTEN, MEZ, JESSE BENJAMIN · 2019 to 2023
$5.9M
Improving Chronic Disease Outcomes Across the Lifespan by Addressing Structural RacismR01NR020752 · NINR · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Arvin Garg · 2022 to 2026
$4.1M
Cerebrovascular Remodeling and Neurodegenerative Changes in Alzheimer's DiseaseR01AG075876 · NIA · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI Thor Stein, JOSEPH ZAIA · 2022 to 2026
$3.9M
Risk for Later-Life Cognitive Impairment, Neurobehavioral Dysregulation, and Dementia in Former Soccer and American Football Players: The Head Impact and Trauma Surveillance Study (HITSS)R01NS119651 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ALOSCO, MICHAEL · 2021 to 2025
$3.9M
Alzheimer's Association NIRG-305779, NIRG-362697BLRD Merit Award I01BX005933 (CTE-AD)BLRD VA I01 BX002466BLRD VA I01 BX005161BLRD VA I01 BX005933BLRD VA IK2 BX004349Department of Defense Peer Reviewed Alzheimer's Research Program PRARP #13267017EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT 5R01HD104772Military Exposures Research Program Award United States (U.S.) Department of Veterans Affairs Biomedical Laboratory R&D Service (ALS MERP) 1I01BX005161National Center for PTSD U.S. Department of Veterans AffairsNational institute of Aging 1RF1NS122854National Institute of Aging P30AG066514-06National Institute of Aging R01AG075876-Zhang, Stein, ZaiaNational Institute of Aging R01AG087199National Institute of Aging R01AG090553National Institute of Aging R01NS132290National Institute of Aging R01NS139383National Institute of Aging Boston University AD Research P30AG072978-McKeeNational Institute of Aging Boston University AD Research Center P30AG072978-McKeeNational Institute of Aging, National Institute of Neurological Disorders and Stroke 5R01 NS119651-04, National Institute of Neurological Disorders and Stroke RF1NS122854- AloscoNHLBI NIH HHS 75N92019D00031NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG072978NIA NIH HHS R01 AG061028NIA NIH HHS R01AG061028NIA NIH HHS R01 AG075876NIA NIH HHS R01 AG087199NIA NIH HHS R01 AG090553NICHD NIH HHS R01 HD104772NIH HHS 75N92024R0245NIH/NIA 3P30-AG13846-23NINDS NIH HHS 1U01 NS137483-01NINDS NIH HHS R01 NS093870NINDS NIH HHS R01NS093870NINDS NIH HHS R01 NS119651NINDS NIH HHS R01 NS122854NINDS NIH HHS R01 NS132290NINDS NIH HHS R01 NS139383NINDS NIH HHS R01 NS142076NINDS NIH HHS R01NS142076NINDS NIH HHS RF1 NS122854NINDS NIH HHS RF1NS122854- AloscoNINDS NIH HHS U01 NS086659NINDS NIH HHS U01 NS137483NINDS NIH HHS U54 NS115266NINDS NIH HHS U54NS115266NINDS NIH HHS U54NS115266-McKeeNINR NIH HHS 5R01 NR020752-03NINR NIH HHS R01 NR020752United States Department of Veterans Affairs, Veterans Health Administration, Veterans Affairs Biorepository BX002466Veterans Affairs BX004349
6 · The paper itself

Abstract

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease caused by repetitive head impacts (RHI). However, individuals with similar RHI exposure can show differing pathology, suggesting a role for genetic variation. A common Transmembrane Protein 106B (TMEM106B) risk variant is associated with greater CTE severity, though its mechanism remains unclear. To determine whether TMEM106B alters the inflammatory response to pathology in CTE, we examined associations between microglia, via immunohistochemistry, and inflammatory cytokines, via immunoassay, in brain donors with CTE with and without the risk genotype (rs3173615). We analyzed 323 RHI-exposed brain donors: 55 without pathology (controls) and 268 with CTE. Regression models tested associations between TMEM106B risk and CTE presence, CTE stage, TDP-43, and dementia in those < = 65 and > 65 years of age. Within a subset of 122 brain donors, we examined associations between microglia, cytokines, and pathology stratified by TMEM106B genotype. Among donors > 65 years old, the TMEM106B risk genotype was associated with increased CTE stage (OR = 2.748 [95% CI 1.183-6.383], p = 0.019), comparable to the effect of playing > 8 years of contact sports, and with greater odds of having TDP-43 inclusions (OR = 3.649 [95% CI 1.278-10.422], p = 0.016). In donors < = 65, TMEM106B risk was associated with higher odds of dementia (OR = 6.912 [95% CI 2.015-23.705], p = 0.002). TMEM106B gene variation had a significant effect on associations between inflammatory markers and CTE-related pathology. In the protective genotype, IL-8 and IL-6 demonstrated positive associations with CD68, TREM2, and tau pathology within the dorsolateral prefrontal cortex. In the risk genotype, IFN-γ, IL-4, TNF-α, TNF-β, and IL-10 demonstrated negative associations with TREM2 (p's < 0.05), and TNF-α was negatively associated with cortical tau (p = 0.003). These results suggest that the microglial production of TREM2-associated cytokines and their association with pathology is aberrant in the TMEM106B risk genotype in CTE. Overall, TMEM106B rs3173615 is associated with an increased risk of developing higher stage CTE and TDP-43 pathology, potentially via impaired microglial activation and aberrant cytokine production.

Indexed as

Chronic Traumatic EncephalopathyCytokinesMembrane ProteinsMicrogliaNerve Tissue ProteinsAdultAgedBrainDNA-Binding ProteinsFemaleGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideCytokinesDNA-Binding ProteinsMembrane ProteinsNerve Tissue ProteinsTMEM106B protein, humanCTECytokinesMicrogliaNeuropathologyRHITMEM106B

Identifiers

PMID41264095
PMCPMC12634763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.